Envarsus XR® (tacrolimus) – New indication
December 19, 2018 - Veloxis announced the FDA approval of Envarsus XR (tacrolimus) extended-release tablets, for the prophylaxis of organ rejection in de novo kidney transplant patients in combination with other immunosuppressants.
Download PDF
